January 14, 2021

The multinational biopharmaceutical company Amgen has announced it will pay $240 million in upfront cash and milestone payments for molecules targeting autoimmune conditions from Ann Arbor, MI-based Evoq Therapeutics, a spinoff of research from the University of Michigan. Evoq, founded by Profs. Anna Schwendeman and James Moon, is named for the targeted dendritic cells the company uses to “evoke” immune tolerance in regulatory T cells.

Read more about the pair's research and their new partnership with Amgen.